

The board of directors' statement under Chapter 18 Section 4 of the Swedish Companies Act – Medicover AB (publ)

Due to the dividend proposal by the board of directors of Medicover AB (publ) to the annual general meeting 2022 the board of directors hereby submits the following statement under Chapter 18 Section 4 of the Swedish Companies Act.

The board of directors has proposed a dividend of EUR 0.12 per share. In total the proposed dividend amounts to EUR 17,802,066.12 based on the total number of shares entitled to dividend, which amounts to 148,350,551 shares.

The board of directors considers in view of what is stated below that the proposed dividend, taking into account the proposed authorisation for the board of directors to resolve to acquire own shares, is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, and the need for the company and the group, respectively, to strengthen the balance sheet, liquidity and position in other aspects.

Equity

The board of directors considers, taking into account the proposed acquisitions of own shares, that the equity of the company and the group, will be of sufficient amount after the proposed dividend. The board of directors has in connection hereto contemplated the business' nature, scale and the risks that the business is associated with and the current economic situation, historical development and forecasts for the company and the group, respectively, as well as for the market.

Need of strengthening the balance sheet, liquidity and position in other aspects

The board of directors has made a comprehensive assessment of the company's and the group's financial position and its respective ability to fulfill its undertakings in the long term. As stated in the annual report for the financial year 2021, the non-restricted equity of the company as per 31 December 2021 was EUR 579,530,564. As per the same date the group's total equity attributable to the shareholders of the company was approximately EUR 517,560,000.

The proposed dividend, taking into account the proposed authorisation to acquire own shares, does not affect the company's or the group's ability to in due time fulfill present and anticipated financial obligations or the ability to implement planned investments.

The board of directors has also considered other known matters that may affect the company's and the group's financial position and that have not been considered within the scope of the above stated. No other matter that would make the proposed dividend, taking into account the proposed authorisation to acquire own shares, unjustifiable has been identified during such analysis.

Stockholm in March 2022
Medicover AB (publ)
The board of directors